Share on

Global Biomarkers Market Size, Share, Trends, COVID-19 Impact and Growth Analysis Report – Segmented By Product, Biomarker Type (Safety Biomarkers, Efficacy Biomarkers), Application, Disease Indications and Region – Industry Forecast (2022 to 2027).

Published: January, 2022
ID: 164
Pages: 175
Formats: report pdf report excel report power bi report ppt

Biomarkers Market Size (2022 to 2027)

As per the report, the global biomarkers market size is predicted to grow USD 76.38 billion by 2027 from USD 40.66 billion in 2022. This market is showcasing an increasing pace of 13.44% CAGR from 2022 to 2027.

Biomarkers play a crucial role in diagnosing and treating various diseases such as cancer, cardiovascular problems, etc. A combination of biomarkers with novel drugs is evaluating effective treatment procedures for different conditions. With the help of technological advancements, biomarkers are designed to treat neurological diseases by measuring biomolecules that track the brain's health. The launch of biomarker signature makes the treatment of neurological disease easier by diagnosing through non-invasive testing methods. Biomarkers are very safe and give valid results with high precision, and this property is also making the market move forward.

Impact of COVID-19 on the global biomarkers market:

The World Health Organization was declared COVID-19 on March 11, 2020, as a global pandemic and announced healthcare emergence. The recent novel coronavirus causes SARS-COV-2. The emergence of the outbreak has affected almost all sectors of the economy. Pandemic has kept many lives at risk, including nationwide lockdown implemented and a ban on transportation.

The increase in the number of covid-19 positive cases has led to the massive development of the bio-markers technologies market. The molecular markers in the blood are used to prevent the virus and the diseases it causes. Amplified studies have been launched into study results about understanding the pathophysiology and clinical progress of COVID-19. Biomarkers are used for categorizing early infection and individuals who are in danger of increasing critical conditions and requiring hospital care. Biomarkers have played an essential role in clinical decision-making and the number of infectious diseases and treatment procedures. It has become mandatory to access biomarkers to determine the severity of illness and suitable resource allocation.


The rising incidence of cancer, growing CROs, and increasing prevalence of chronic diseases worldwide is primarily expanding the global biomarkers market.

In urban areas, people are more likely to adopt sedentary lifestyles, causing a high possibility of being prone to various chronic diseases. Growing chronic disease incidence, majorly cancer, CVDs, and diabetes, are demanding more research initiatives to favor market growth.

Increasing research and development spending, rising healthcare expenditure, and growing demand for biomarkers in the diagnostic field are crucial factors driving growth in the global biomarkers market. Besides, an increasing number of the low costs of clinical trials in emerging countries, growth initiatives in biomarkers research, increasing growth of information technology, growing demand for drug discovery are further propelling the growth of the global biomarkers market.

Increasing initiative steps by government organizations worldwide to reduce the cost of treatment procedures and growing focus on personalized medicine are also lavishing the demand of the biomarkers market. Rising prevalence to increase the productivity of drugs in pharmaceutical companies and peoples demand the prevention of the disease by diagnosing as early as possible further escalates the market growth.

Growing investments in healthcare centers by both public and private organizations, the rise in the priority for the minimally invasive and non-invasive treatment procedures also prompt the demand of this market.


Huge investment needs and unfavorable reimbursement rules are major restraints to the global biomarkers market growth. Costs associated with the testing processes are very high, which is estimated to inhibit the market to some extent.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Product, Type, Application, Disease Indications, and Region.

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities.

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.


This research report on the global biomarkers market has been segmented based on the product, type, application, disease indications, and region.

Biomarkers Market - By Product:

  • Consumables
  • Software
  • Services

Based on product type, consumables product type is expected to hold a leading share in the global biomarkers market during the forecast period. Increasing awareness over the utilization of various devices to improve therapeutic procedures elevates the demand for this segment. Rising spending on healthcare is to boost up the growth rate of the market. Also, the increasing popularity of targeted therapies is the demand of the biomarkers market.

Biomarkers Market - By Type:

  • Safety Biomarkers
  • Efficacy Biomarkers
  • Validation Biomarkers

Based on biomarkers type, the safety biomarkers segment is predicted to register the largest share in the global market, whereas efficacy biomarkers are growing tremendously over the past few years. Usage of safe products leads to a high success rate and promotes the well-being of the patient after surgeries are broadening the market demand. People's need for appropriate treatment procedures by diagnosing the disease is also enhancing the growth rate of this market.

Biomarkers Market - By Application:

  • Diagnostics Developments
  • Drug Discovery & Developments
  • Personalized Medicine
  • Disease Risk Assessment

Based on the application, the diagnostic developments segment is gaining traction and estimated to dominate throughout the forecast period. The rise in capital income in both developed and developing countries are gearing up the market demand. Also, increasing the scale of hospitals is leveraging the growth rate of the market.

Biomarkers Market - By Disease Indications:

  • Cancer
  • Cardiovascular
  • Neurological
  • Immunological Disorders

Based on disease indications, the cancer segment is the most dominant among all and predicted to grow at a healthy rate. The increasing geriatric population and rising incidences of cancer diseases are escalating the demand for the biomarkers market. Increasing new cancer patients and the rising number of deaths due to cancer expand the scope for the cancer disease indication segment.

Biomarkers Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

North America held a significant market share of 39.0% of the global biomarkers market in 2019, whereas Asia-Pacific is estimated to grow at the highest CAGR of 16.20% during the forecast period.


Some of the noteworthy companies operating in the global biomarkers market profiled in this report are Bio-Rad Laboratories (U.S.), Qiagen N.V. (Netherlands), Enzo Biochem (U.S.), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), EKF Diagnostics Holdings plc. (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.)


  • In March 2020, Meso Scale Discovery, a Meso Scale Diagnostics division, announced its Biomarkers services at AAPSNational Biotechnology Conference. 
  • In February 2020, Enzo Biochem announced that its subsidiary, Enzo clinical labs, Inc., had received New York State Approval for its CT/NG/Tv tests using liquid-based cytology sample collection on its proprietary Gen-Flex platform. 
  • In February 2020, QGEnN announced the receipt of CE Mark for its therascreen PIK3CA Rotor-Gene Q PCR Kit and its subsequent Europe Launch. 
  • In July 2019, Enzo Biochem Inc. announced several vital transformative initiatives in its lab business unit designed to propel and accelerate the growth. 
  • In August 2018, Enzo Biochem, an integrated diagnostic and therapeutic company, announced implementing its growth strategy. It has agreed to purchase a commercial facility. 
  • In December 2018, Singulex announced the granting of a significant European patent covering methods for determining myocardial. 
  • In April 2016, DiagnoCure Inc. announced that its board of directors has decided, subject to shareholder's approval, to proceed with the voluntary liquidation and dissolution of Quebec's Business Corporations Act. 

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample